文献速递垂体与肾上腺疾病

p300抑制剂A-485在生长激素型垂体腺瘤中发挥抗肿瘤活性

The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究检测生长激素型垂体腺瘤(GHPA)与正常垂体组织中p300的表达,并用siRNA敲低及p300选择性抑制剂A-485处理,观察其对细胞周期、增殖、凋亡和激素分泌的影响。结果显示GHPA组织中p300高表达,A-485在体外和体内抑制细胞生长及GH分泌,并下调Pttg1、c-Myc、cAMP及PI3K/AKT/mTOR通路相关癌基因。作者认为抑制p300是GHPA有前景的治疗方向。

要点

  • GHPA组织中p300表达高于正常垂体组织。
  • siRNA敲低p300可抑制细胞增殖与克隆形成。
  • A-485在体外和体内抑制细胞生长及GH分泌。

核心结论

  • 作者认为,用选择性抑制剂A-485抑制组蛋白乙酰转移酶p300是生长激素型垂体腺瘤有前景的治疗方式。

研究设计与样本

  • 检测GHPA与正常垂体组织中p300的表达,并用siRNA进行基因敲低。
  • 通过流式细胞术、ELISA、Western blotting和qRT-PCR研究A-485对细胞周期、增殖、凋亡和激素分泌的作用。
  • 通过RNA测序、生物信息学分析及后续验证实验探讨A-485的潜在生物学机制。

主要发现

  • 与正常垂体组织相比,GHPA组织中p300高表达。
  • 敲低p300可抑制细胞增殖和克隆形成。
  • A-485处理在体外和体内均抑制细胞生长并抑制GH分泌。
  • A-485可下调Pttg1、c-Myc、cAMP及PI3K/AKT/mTOR信号通路相关基因等癌基因的表达或活性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Growth hormone pituitary adenoma (GHPA), a major subtype of pituitary adenoma (PA), can lead to progressive somatic disfigurement, multiple complications, and even increased mortality. The efficacy of current treatments is limited; thus, a novel pharmacological treatment is urgently needed. As a histone acetyltransferase (HAT) coactivator, p300 can regulate the transcription of several genes that are crucial for PA tumorigenesis and progression. However, the role of p300 and its catalytic inhibitor in GHPA is still unclear. OBJECTIVE: We aimed to identify the expression of p300 in GHPA and in normal pituitary glands. METHODS: The expression of p300 was detected in GHPA and normal pituitary tissues. Genetic knockdown was performed by siRNA. The efficacy of the p300 inhibitor A-485 in the cell cycle, proliferation, apoptosis, and hormone secretion was investigated by flow cytometry, ELISAs, Western blotting, and qRT-PCR. RNA sequencing, bioinformatic analysis, and subsequent validation experiments were performed to reveal the potential biological mechanism of A-485. RESULTS: High expression of p300 was found in GHPA tissues compared with normal pituitary tissues. Knockdown of p300 inhibited cell proliferation and clone formation. Treatment with A-485 suppressed cell growth and inhibited the secretion of GH in vitro and in vivo. Further mechanistic studies showed that A-485 could downregulate the expression or activity of several oncogenes, such as genes in the Pttg1, c-Myc, cAMP and PI3K/AKT/mTOR signaling pathways, which are crucial for PA tumorigenesis and progression. CONCLUSION: Our findings demonstrate that inhibition of HAT p300 by its selective inhibitor A-485 is a promising therapy for GHPA.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ji C, Xu W, Ding H, et al. The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma. J Clin Endocrinol Metab. 2022. PMID: 35247260. doi:10.1210/clinem/dgac128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。